OrthoPediatrics Corp. (NASDAQ:KIDS – Get Free Report) Director David Pelizzon sold 10,131 shares of the business’s stock in a transaction on Tuesday, September 1st. The shares were sold at an average price of $23.10, for a total transaction of $234,026.10. Following the completion of the transaction, the director directly owned 6,526,633 shares of the company’s stock, valued at $150,765,222.30. This trade represents a 0.15% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this hyperlink.
OrthoPediatrics Stock Performance
Shares of OrthoPediatrics stock opened at $22.59 on Friday. The company has a market capitalization of $589.82 million, a PE ratio of -13.45 and a beta of 0.99. OrthoPediatrics Corp. has a 12 month low of $14.42 and a 12 month high of $26.74. The company has a current ratio of 4.78, a quick ratio of 2.17 and a debt-to-equity ratio of 0.28. The stock’s fifty day simple moving average is $21.74 and its 200 day simple moving average is $18.84.
OrthoPediatrics (NASDAQ:KIDS – Get Free Report) last posted its earnings results on Tuesday, August 4th. The company reported ($0.26) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.30) by $0.04. OrthoPediatrics had a negative return on equity of 8.10% and a negative net margin of 15.72%.The firm had revenue of $70.51 million during the quarter, compared to analysts’ expectations of $68.21 million. On average, research analysts predict that OrthoPediatrics Corp. will post -1.14 EPS for the current year.
Institutional Inflows and Outflows
Analyst Upgrades and Downgrades
Several research firms recently issued reports on KIDS. Piper Sandler reiterated an “overweight” rating and set a $25.00 price target (up from $22.00) on shares of OrthoPediatrics in a research report on Wednesday, August 5th. BTIG Research upped their price target on OrthoPediatrics from $24.00 to $29.00 and gave the stock a “buy” rating in a research note on Thursday, August 20th. Truist Financial set a $22.00 target price on OrthoPediatrics in a report on Wednesday, August 5th. Weiss Ratings upgraded shares of OrthoPediatrics from a “sell (e+)” rating to a “sell (d-)” rating in a report on Wednesday, August 5th. Finally, Needham & Company LLC upped their price objective on shares of OrthoPediatrics from $30.00 to $35.00 and gave the stock a “buy” rating in a research report on Wednesday, August 5th. Nine equities research analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has given a Sell rating to the company. Based on data from MarketBeat, the stock has a consensus rating of “Moderate Buy” and an average target price of $26.44.
Get Our Latest Research Report on OrthoPediatrics
About OrthoPediatrics
OrthoPediatrics Corp., founded in 2007 and headquartered in Warsaw, Indiana, is a medical device company dedicated exclusively to providing orthopedic solutions for children. The company focuses on developing, manufacturing and marketing a broad portfolio of implants and instruments designed to address a wide range of pediatric conditions, including trauma, deformity correction, spine disorders and sports injuries.
The company’s product lines include locking plates and screws for upper and lower extremity reconstruction, intramedullary nails for femur and tibia stabilization, and specialized systems such as the MAGEC Magnetic Growth Rod for treatment of early-onset scoliosis.
Featured Articles
- Five stocks we like better than OrthoPediatrics
- The Path to $230 Billion: Broadcom Outlines the Next Phase of Its AI Growth Story
- NVIDIA’s Hugging Face Deal Raises a Bigger Question About Its AI Moat Now
- Dropping the Dough: Yum! Brands Strategically Trims the Fat
- These 3 Stock Charts Just Flashed the Dreaded Death Cross Pattern
Receive News & Ratings for OrthoPediatrics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for OrthoPediatrics and related companies with MarketBeat.com's FREE daily email newsletter.
